- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Toshiba shows PowerVision cardiac systems
Toshiba America Medical Systems showcased two models of cardiac ultrasound systems, members of the company’s PowerVision family, at this year’s American College of Cardiology convention in March. The PowerVision 6000 was released two years ago
Toshiba America Medical Systems showcased two models of cardiac ultrasound systems, members of the companys PowerVision family, at this years American College of Cardiology convention in March.
The PowerVision 6000 was released two years ago and the PowerVision 8000 was released at the Radiological Society of North Americas annual meeting last year. A combination of hardware and software allows both systems to perform head-to-toe scanning using a number of applications, including contrast agents, harmonic tissue imaging, and digital imaging.
The difference between the two systems lies in the number of channels, said Scott Yarde, Toshibas ultrasound marketing manager. The 6000 model has 256 channels and the 8000 model has 512 channels.
In addition to plug-and-play transducers, the PowerVision 8000 contains an integrated digital information system package that Tustin, CA-based Toshiba has named PowerView. The PowerView package supports all DICOM service classes and stress echo software. Three-dimensional capabilities and live digital video streaming for telemedicine are being developed.
Clinicians can purchase the PowerView package as an option for the 6000 model. Both systems are capable of quantifying blood flow and perfusion, but these studies have yet to be widely used, Yarde said. The PowerVision 8000 is most appropriate for large, multidepartment hospitals, he said.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
